Combining DNA methylation features and clinical characteristics predicts ketamine treatment response for PTSD.
iScience January 16, 2026 Amir Valizadeh, John D Roache, Xinyu Zhang et al. 2 citations
Post-traumatic stress disorder (PTSD) exhibits extensive clinical and biological variability, making treatment challenging. The Consortium to Alleviate PTSD (CAP)-ketamine trial, the largest randomized study of ketamine for PTSD, found no overall benefit of ketamine over placebo, underscoring the necessity to identify responsive subgroups. Using pre-treatment blood DNA methylation profiles and...